)
)
Enhancer heterogeneity in leukaemia drives patient specific transcriptional profiles
- Even though many targeted therapies have an improved patient response rate, many patients still either fail to respond or relapse for reasons that are not always clear.
- Using the high resolution 3C method Micro-Capture-C (MCC), we have identified shared as well as patient sample-specific neo-enhancers
- The presence of patient sample-specific enhancers helps explain the transcriptional diversity observed between patients
